Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 13/2023

22.08.2023 | Original Article

Robust deep learning-based PET prognostic imaging biomarker for DLBCL patients: a multicenter study

verfasst von: Chong Jiang, Chunjun Qian, Zekun Jiang, Yue Teng, Ruihe Lai, Yiwen Sun, Xinye Ni, Chongyang Ding, Yuchao Xu, Rong Tian

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 13/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

To develop and independently externally validate robust prognostic imaging biomarkers distilled from PET images using deep learning techniques for precise survival prediction in patients with diffuse large B cell lymphoma (DLBCL).

Methods

A total of 684 DLBCL patients from three independent medical centers were included in this retrospective study. Deep learning scores (DLS) were generated from PET images using deep convolutional neural network architecture known as VGG19 and DenseNet121. These DLSs were utilized to predict progression-free survival (PFS) and overall survival (OS). Furthermore, multiparametric models were designed based on results from the Cox proportional hazards model and assessed through calibration curves, concordance index (C-index), and decision curve analysis (DCA) in the training and validation cohorts.

Results

The DLSPFS and DLSOS exhibited significant associations with PFS and OS, respectively (P<0.05) in the training and validation cohorts. The multiparametric models that incorporated DLSs demonstrated superior efficacy in predicting PFS (C-index: 0.866) and OS (C-index: 0.835) compared to competing models in training cohorts. In external validation cohorts, the C-indices for PFS and OS were 0.760 and. 0.770 and 0.748 and 0.766, respectively, indicating the reliable validity of the multiparametric models. The calibration curves displayed good consistency, and the decision curve analysis (DCA) confirmed that the multiparametric models offered more net clinical benefits.

Conclusions

The DLSs were identified as robust prognostic imaging biomarkers for survival in DLBCL patients. Moreover, the multiparametric models developed in this study exhibited promising potential in accurately stratifying patients based on their survival risk.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Vodicka P, Klener P, Trneny M. Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options. Onco Targets Ther. 2022;6(15):1481–501.CrossRef Vodicka P, Klener P, Trneny M. Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options. Onco Targets Ther. 2022;6(15):1481–501.CrossRef
3.
Zurück zum Zitat Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022;110:102443.CrossRefPubMed Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022;110:102443.CrossRefPubMed
4.
Zurück zum Zitat Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.CrossRefPubMed Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.CrossRefPubMed
5.
Zurück zum Zitat Kostakoglu L, Chauvie S. PET-derived quantitative metrics for response and prognosis in lymphoma. PET Clin. 2019;14(3):317–29.CrossRefPubMed Kostakoglu L, Chauvie S. PET-derived quantitative metrics for response and prognosis in lymphoma. PET Clin. 2019;14(3):317–29.CrossRefPubMed
6.
Zurück zum Zitat Morin RD, Arthur SE, Hodson DJ. Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes? Br J Haematol. 2022;196(4):814–29.CrossRefPubMed Morin RD, Arthur SE, Hodson DJ. Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes? Br J Haematol. 2022;196(4):814–29.CrossRefPubMed
7.
Zurück zum Zitat McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017Feb;168(4):613–28.CrossRefPubMed McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017Feb;168(4):613–28.CrossRefPubMed
9.
Zurück zum Zitat Zhang X, Zhang Y, Zhang G, Qiu X, Tan W, Yin X, et al. Deep learning with radiomics for disease diagnosis and treatment: challenges and potential. Front Oncol. 2022;17(12):773840.CrossRef Zhang X, Zhang Y, Zhang G, Qiu X, Tan W, Yin X, et al. Deep learning with radiomics for disease diagnosis and treatment: challenges and potential. Front Oncol. 2022;17(12):773840.CrossRef
10.
Zurück zum Zitat Tufail AB, Ma YK, Kaabar MKA, Martínez F, Junejo AR, Ullah I, et al. Deep learning in cancer diagnosis and prognosis prediction: a minireview on challenges, recent trends, and future directions. Comput Math Methods Med. 2021;31(2021):9025470. Tufail AB, Ma YK, Kaabar MKA, Martínez F, Junejo AR, Ullah I, et al. Deep learning in cancer diagnosis and prognosis prediction: a minireview on challenges, recent trends, and future directions. Comput Math Methods Med. 2021;31(2021):9025470.
11.
Zurück zum Zitat Zhao X, Liang YJ, Zhang X, Wen DX, Fan W, Tang LQ, et al. Deep learning signatures reveal multiscale intratumor heterogeneity associated with biological functions and survival in recurrent nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022;49(8):2972–82.CrossRefPubMed Zhao X, Liang YJ, Zhang X, Wen DX, Fan W, Tang LQ, et al. Deep learning signatures reveal multiscale intratumor heterogeneity associated with biological functions and survival in recurrent nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022;49(8):2972–82.CrossRefPubMed
12.
Zurück zum Zitat Yan J, Zhao Y, Chen Y, Wang W, Duan W, Wang L, et al. Deep learning features from diffusion tensor imaging improve glioma stratification and identify risk groups with distinct molecular pathway activities. EBioMedicine. 2021;72:103583.CrossRefPubMedPubMedCentral Yan J, Zhao Y, Chen Y, Wang W, Duan W, Wang L, et al. Deep learning features from diffusion tensor imaging improve glioma stratification and identify risk groups with distinct molecular pathway activities. EBioMedicine. 2021;72:103583.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Jiang Y, Zhang Z, Yuan Q, Wang W, Wang H, Li T, et al. Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study. Lancet Digit Health. 2022;4(5):e340–50.CrossRefPubMed Jiang Y, Zhang Z, Yuan Q, Wang W, Wang H, Li T, et al. Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study. Lancet Digit Health. 2022;4(5):e340–50.CrossRefPubMed
14.
Zurück zum Zitat Deng K, Wang L, Liu Y, Li X, Hou Q, Cao M, et al. A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: a multicenter, prognostic study. EClinicalMedicine. 2022;1(51):101541.CrossRef Deng K, Wang L, Liu Y, Li X, Hou Q, Cao M, et al. A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: a multicenter, prognostic study. EClinicalMedicine. 2022;1(51):101541.CrossRef
15.
Zurück zum Zitat Hiremath A, Shiradkar R, Fu P, Mahran A, Rastinehad AR, Tewari A, et al. An integrated nomogram combining deep learning, prostate imaging-reporting and data system (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study. Lancet Digit Health. 2021;3(7):e445–54.CrossRefPubMedPubMedCentral Hiremath A, Shiradkar R, Fu P, Mahran A, Rastinehad AR, Tewari A, et al. An integrated nomogram combining deep learning, prostate imaging-reporting and data system (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study. Lancet Digit Health. 2021;3(7):e445–54.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Miyawaki K, Sugio T. Lymphoma microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification. J Clin Exp Hematop. 2022;62(3):127–35.CrossRefPubMedPubMedCentral Miyawaki K, Sugio T. Lymphoma microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification. J Clin Exp Hematop. 2022;62(3):127–35.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Bera K, Braman N, Gupta A, Velcheti V, Madabhushi A. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol. 2022;19(2):132–46.CrossRefPubMed Bera K, Braman N, Gupta A, Velcheti V, Madabhushi A. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol. 2022;19(2):132–46.CrossRefPubMed
18.
Zurück zum Zitat Yuan C, Shi Q, Huang X, Wang L, He Y, Li B, et al. Multimodal deep learning model on interim [18F]FDG PET/CT for predicting primary treatment failure in diffuse large B-cell lymphoma. Eur Radiol. 2023;33(1):77–88.CrossRefPubMed Yuan C, Shi Q, Huang X, Wang L, He Y, Li B, et al. Multimodal deep learning model on interim [18F]FDG PET/CT for predicting primary treatment failure in diffuse large B-cell lymphoma. Eur Radiol. 2023;33(1):77–88.CrossRefPubMed
19.
Zurück zum Zitat Chang CC, Chen CH, Hsieh JG, Jeng JH. Iterated cross validation method for prediction of survival in diffuse large B-cell lymphoma for small size dataset. Sci Rep. 2023;13(1):1438.CrossRefPubMedPubMedCentral Chang CC, Chen CH, Hsieh JG, Jeng JH. Iterated cross validation method for prediction of survival in diffuse large B-cell lymphoma for small size dataset. Sci Rep. 2023;13(1):1438.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Guo R, Hu X, Song H, Xu P, Xu H, Rominger A, et al. Weakly supervised deep learning for determining the prognostic value of 18F-FDG PET/CT in extranodal natural killer/T cell lymphoma, nasal type. Eur J Nucl Med Mol Imaging. 2021;48(10):3151–61.CrossRefPubMedPubMedCentral Guo R, Hu X, Song H, Xu P, Xu H, Rominger A, et al. Weakly supervised deep learning for determining the prognostic value of 18F-FDG PET/CT in extranodal natural killer/T cell lymphoma, nasal type. Eur J Nucl Med Mol Imaging. 2021;48(10):3151–61.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Trivizakis E, Papadakis GZ, Souglakos I, Papanikolaou N, Koumakis L, Spandidos DA, et al. Artificial intelligence radiogenomics for advancing precision and effectiveness in oncologic care (Review). Int J Oncol. 2020;57(1):43–53.CrossRefPubMedPubMedCentral Trivizakis E, Papadakis GZ, Souglakos I, Papanikolaou N, Koumakis L, Spandidos DA, et al. Artificial intelligence radiogenomics for advancing precision and effectiveness in oncologic care (Review). Int J Oncol. 2020;57(1):43–53.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Bodalal Z, Trebeschi S, Nguyen-Kim TDL, Schats W, Beets-Tan R. Radiogenomics: bridging imaging and genomics. Abdom Radiol (NY). 2019;44(6):1960–84.CrossRefPubMed Bodalal Z, Trebeschi S, Nguyen-Kim TDL, Schats W, Beets-Tan R. Radiogenomics: bridging imaging and genomics. Abdom Radiol (NY). 2019;44(6):1960–84.CrossRefPubMed
23.
Zurück zum Zitat Jiang Y, Jin C, Yu H, Wu J, Chen C, Yuan Q, et al. Development and validation of a deep learning ct signature to predict survival and chemotherapy benefit in gastric cancer: a multicenter, retrospective study. Ann Surg. 2021;274(6):e1153–61.CrossRefPubMed Jiang Y, Jin C, Yu H, Wu J, Chen C, Yuan Q, et al. Development and validation of a deep learning ct signature to predict survival and chemotherapy benefit in gastric cancer: a multicenter, retrospective study. Ann Surg. 2021;274(6):e1153–61.CrossRefPubMed
24.
Zurück zum Zitat Huang G, Liu Z, Pleiss G, Maaten LV, Weinberger KQ. Convolutional networks with dense connectivity. IEEE Trans Pattern Anal Mach Intell. 2022;44(12):8704–16.CrossRefPubMed Huang G, Liu Z, Pleiss G, Maaten LV, Weinberger KQ. Convolutional networks with dense connectivity. IEEE Trans Pattern Anal Mach Intell. 2022;44(12):8704–16.CrossRefPubMed
25.
Zurück zum Zitat Xiao L , Bahri Y , Sohl-Dickstein J ,et al. Dynamical isometry and a mean field theory of CNNS: how to train 10,000-layer vanilla convolutional neural networks. International Conference on Machine Learning. PMLR, 2018. Xiao L , Bahri Y , Sohl-Dickstein J ,et al. Dynamical isometry and a mean field theory of CNNS: how to train 10,000-layer vanilla convolutional neural networks. International Conference on Machine Learning. PMLR, 2018.
26.
Zurück zum Zitat Nichani, E., A. Radhakrishnan, and C. Uhler. Do deeper convolutional networks perform better?. International Conference on Machine Learning. 2021. Nichani, E., A. Radhakrishnan, and C. Uhler. Do deeper convolutional networks perform better?. International Conference on Machine Learning. 2021.
27.
Zurück zum Zitat Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2017–22.CrossRefPubMed Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2017–22.CrossRefPubMed
28.
Zurück zum Zitat Mikhaeel NG, Smith D, Dunn JT, Phillips M, Møller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209–19.CrossRefPubMedPubMedCentral Mikhaeel NG, Smith D, Dunn JT, Phillips M, Møller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209–19.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Shagera QA, Cheon GJ, Koh Y, Yoo MY, Kang KW, Lee DS, et al. Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging. 2019;46(7):1417–27.CrossRefPubMed Shagera QA, Cheon GJ, Koh Y, Yoo MY, Kang KW, Lee DS, et al. Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging. 2019;46(7):1417–27.CrossRefPubMed
30.
Zurück zum Zitat Chiu BC, Hou N. Epidemiology and etiology of non-Hodgkin lymphoma. Cancer Treat Res. 2015;165:1–25.CrossRefPubMed Chiu BC, Hou N. Epidemiology and etiology of non-Hodgkin lymphoma. Cancer Treat Res. 2015;165:1–25.CrossRefPubMed
Metadaten
Titel
Robust deep learning-based PET prognostic imaging biomarker for DLBCL patients: a multicenter study
verfasst von
Chong Jiang
Chunjun Qian
Zekun Jiang
Yue Teng
Ruihe Lai
Yiwen Sun
Xinye Ni
Chongyang Ding
Yuchao Xu
Rong Tian
Publikationsdatum
22.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 13/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-023-06405-y

Weitere Artikel der Ausgabe 13/2023

European Journal of Nuclear Medicine and Molecular Imaging 13/2023 Zur Ausgabe